Cas:19984-56-6 2-(1-Adamantyl)isoquinolinium bromide manufacturer & supplier

Chemical Name:2-(1-Adamantyl)isoquinolinium bromide

CAS.NO:19984-56-6

Synonyms:2-(1-Adamantyl)isoquinolinium bromide

Molecular Formula:C₁₉H₂₂BrN

Molecular Weight:344.28868

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-(1-Adamantyl)isoquinolinium bromide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(1-Adamantyl)isoquinolinium bromide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(1-Adamantyl)isoquinolinium bromide Use and application,2-(1-Adamantyl)isoquinolinium bromide technical grade,usp/ep/jp grade.

Related News: he agency said the drugmaker and Emergent must agree that the FDA can share relevant information about the manufacturing of the doses with regulators where the vaccine is shipped. 2-(1-Adamantyl)isoquinolinium bromide manufacturer Lilly has pledged to address the problems, and said none of them affected drugs in the market. The FDA, which has taken no public action, did not respond to requests for comment. 2-(1-Adamantyl)isoquinolinium bromide supplier On April 8, a group of employees filed an anonymous complaint internally alleging that an executive at its Branchburg, New Jersey, factory had altered documents required by the U.S. Food and Drug Administration. 2-(1-Adamantyl)isoquinolinium bromide vendor Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies. 2-(1-Adamantyl)isoquinolinium bromide factory On April 8, a group of employees filed an anonymous complaint internally alleging that an executive at its Branchburg, New Jersey, factory had altered documents required by the U.S. Food and Drug Administration.